Skip to content

EEG and TMS-based Biomarkers of ALS, MS and FTD

Investigation of EEG and TMS-based Biomarkers of Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Frontotemporal Dementia

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04918251
Enrollment
400
Registered
2021-06-08
Start date
2012-09-30
Completion date
2023-04-30
Last updated
2021-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Multiple Sclerosis

Keywords

EEG, TMS, Neurodegeneration, Network, Electrophysiology, Biomarkers, Cognitive, Behavioural, Motor

Brief summary

The purpose of this observational study is to improve understanding of the biology of why ALS, MS and FTD have different effects on different people and facilitate better measurement of the disease in future drug testing. To do this, brain and spinal cord neural network functionality will be measured over time, in addition to profiling of movement and non-movement symptoms, in large groups of patients, as well as in a population-based sample of the healthy population. Patterns of dysfunction which relate to patients' diagnosis and coinciding and future symptoms which align with categories of patients with similar prognoses will be investigated and their ability to predict incident patients' symptoms in future will be measured.

Detailed description

The aim of this project is to characterize spatiotemporal patterns of central nervous system dysfunction that correlate with clinical features of ALS, MS and FTD, to provide non-invasive electrophysiological measurements that can be used in a clinical setting to inform stratification of patients in clinical trials, and to provide data driven diagnostic and prognostic biomarkers and objective clinical trial outcome measures. Such dysfunction will be investigated by recording single- and paired-pulse transcranial magnetic stimulation (TMS)-associated electromyography (EMG) during rest and by recording electroencephalography (EEG) during rest and during cognitive-motor tasks.

Interventions

PROCEDURE128 electrode electroencephalography (EEG)

128 electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting or performing tasks designed to engage specific cortical motor networks of interest (cognitive, behavioural, motor and sensory)

PROCEDURETranscranial magnetic stimulation (TMS)

Single and paired pulse TMS protocol will be delivered while surface bipolar EMG is recorded over hand muscles to interrogate corticospinal tract function and cortical motor network component functions

Sponsors

Motor Neurone Disease Association, UK
CollaboratorUNKNOWN
Irish Research Council, IE
CollaboratorUNKNOWN
Health Research Board, IE
CollaboratorUNKNOWN
Research Motor Neurone, IE
CollaboratorUNKNOWN
Thierry Latran Foundation, FR
CollaboratorUNKNOWN
ALS Association, USA
CollaboratorUNKNOWN
University of Dublin, Trinity College
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age \>18 years and able to give informed written or verbal (in the presence of two witnesses) consent. * In the case of non-control subjects, a clinical diagnosis of: (i) Probable frontotemporal dementia (FTD) including behavioural variant FTD, semantic dementia or primary progressive aphasia) with supportive brain imaging or known FTD causing genetic mutation (ii) Multiple sclerosis (MS) according to the McDonald criteria (Polman et al., 2011) or (iii) Possible, probable or definite amyotrophic lateral sclerosis (ALS) according to the El Escorial Criteria Revised (Brooks et al. 2000)

Exclusion criteria

* Any diagnosed neurological/muscular disease other than ALS, MS or FTD * Use of neuro- or myo-modulatory medications except riluzole * Inability to participate due to disease-related motor symptoms (e.g. inability to sit for the required time or click the mouse to respond) * Upper body metallic implants * History of seizure disorders in the participant or immediate family members * Anxiety-induced fainting * Regular migraine * Evidence of significant respiratory insufficiency * Sleep time \>2 hours below normal and/or alcohol consumption the night before data collection (in which case, recording session will be rescheduled).

Design outcomes

Primary

MeasureTime frameDescription
Diagnosis-related difference in EEG or TMS measurementsBaseline recordingDifferences in single or paired pulse TMS measures or time and/or frequency domain EEG characteristics between those within each patient cohort and controls
Prognosis-related EEG or TMS measurementsBaseline recordingPatient cohort single or paired pulse TMS measures or time and/or frequency domain EEG characteristics which show significant correlation to cognitive, behavioural, motor and/or sensory task performance, to disease duration or to survival time
Diagnosis-related changes in EEG or TMS measurementsBaseline to final visit assessed up to 2 years after baselineDifferences in rate of change (slope) across time of single or paired pulse TMS measures or time and/or frequency domain EEG characteristics between those within each patient cohort relative to controls
Prognosis-related changes in EEG or TMS measurementsBaseline to final visit assessed up to 2 years after baselineRates of change (slope) across time of patient cohort single or paired pulse TMS measures or time and/or frequency domain EEG characteristics which show significant correlation to cognitive, behavioural, motor and/or sensory task performance, to disease duration or to survival time

Secondary

MeasureTime frameDescription
Diagnosis-specific changes in EEG or TMS measurementsBaseline to final visit assessed up to 2 years after baselineDifferences in rate of change (slope) across time of single or paired pulse TMS measures or time and/or frequency domain EEG characteristics between patient cohorts
Diagnosis-specific difference in EEG or TMS measurementsBaseline recordingDifferences in single or paired pulse TMS measures or time and/or frequency domain EEG characteristics between patient cohorts

Countries

Ireland

Contacts

Primary ContactOrla Hardiman, BSc MB BCh BAO MD FRCPI FAAN
hardimao@tcd.ie+353 1 896 4497
Backup ContactRoisin McMackin, BA PhD
mcmackr@tcd.ie01 896 4497

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026